SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) ("Perseon" or the "Company") today announced the initiation of a multi-organ in vivo ablation zone study for its MicroThermX microwave ablation system designed to provide ablation volumes based on different antenna configurations and varying ablation times in the liver, kidney and lung.
The technology evaluation, which will take place at the University of Louisville, will evaluate both laparoscopic and open surgical approaches with MicroThermX, which are typical treatment regimens for energy ablation. Evaluating ablations in the chosen organs, liver, lung, and kidney, corresponds with today's most common usage for energy ablation.
"The basis for initiating this study was to conduct an analysis of multi-probe MicroThermX' Synchronous Wave Alignment Technology, which is unique in the field of microwave energy ablation," said Robert Martin, MD, PhD, Study Director and Principal Investigator. "The idea that two antennas can be placed in multiple configurations – not exactly parallel to each other – and still provide an efficient ablation is a difference maker in a field where ablation zones can vary to great degrees with systems that require precise positioning."
This study is part of Perseon's INSPIRE 2017 campaign, which was created to strengthen the use of microwave ablation in cancer care and gather relevant clinical data to support the movement.
"This trial is pivotal for Perseon, as it marks the first in vivo trial of its kind for MicroThermX," said Brian A. Meltzer, Chief Medical Officer of Perseon. "The push for real world results reinforces our commitment to clinically relevant data and further shows how our Synchronous Wave Alignment Technology provides added efficiency for physicians in the field of energy ablation."
About Perseon Corporation
Perseon Corporation invests its resources in fighting humanity's worst disease – cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.
Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.
Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Jennifer R. Hoglin Vice President of Global Marketing Phone: (801) 972-5555 Email: email@example.com